Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion
具有人肝细胞趋向性和中和抗体逃避性的AAV载体的合理设计
基本信息
- 批准号:10546241
- 负责人:
- 金额:$ 26.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAlbuminsAmericanAnatomyAnimal ModelAnimalsBindingBiologyBlindnessBlood Component RemovalCanis familiarisCapsidCellsClinicClinicalClinical ResearchClinical TrialsDataDependovirusDirected Molecular EvolutionDiseaseDoseEngineeringFDA approvedFlow CytometryGene DeliveryGene Transduction AgentGene TransferGenetic DiseasesGoalsHepatocyteHigh PrevalenceHumanImmunizeImmunohistochemistryIn VitroIndustryInfectionIntravenous ImmunoglobulinsInvestigationLibrariesLiverLiver diseasesMasksMediatingMendelian disorderMental DepressionMethodsMusMuscular AtrophyMutationOrganPathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePhasePlasmaPlayPopulationPreparationPrevalencePricePrimatesProductionPropertyQuality of lifeRare DiseasesResearch PersonnelRoleSafetySerotypingSerumSpinalSurfaceSystemTechnologyTherapeuticTimeTissuesTractionTropismVariantVirionXenograft ModelXenograft procedureadeno-associated viral vectorbaseclinical developmentcostcross reactivitydelivery vehicleefficacy testingexperimental studygene therapyhumanized mousemortalitymutantneutralizing antibodynovelphase 2 studyrational designsuccesstherapeutic transgenevectorvirtual
项目摘要
Adeno-associated virus (AAV) vectors have been successfully applied in clinical trials in patients with diverse
disorders. Two AAV based gene therapy drugs have been recently approved by the FDA. Luxturna has been
valued at $850,000 for a one-time treatment for a rare form of blindness and Zolgensma priced at $2,100,000
for spinal muscle atrophy. As such, AAV vector based gene therapy is an increasingly attractive market.
Although successful in clinical studies, two concerns restrict broader AAV vector applications for patients
requiring liver targeted AAV gene therapy following systemic administration: low human hepatocyte
transduction and neutralizing antibody (Nab)-mediated inhibition of AAV transduction. Several approaches
have been explored for AAV transduction enhancement or capsid Nab evasion. Engineering of the AAV
capsid presents a very powerful and popular technology that has been extensively studied to develop novel
AAV vectors for enhanced transduction in animal models or Nab escape in vitro. However, it has been
demonstrated that the results from mouse experiments do not recapitulate those of large animals such as
primates and dogs. Thus, the data for AAV variants generated in animal cells and organs may not translate
into successful human applications. Recently, a mouse xenograft model with human hepatocytes has been
used to develop human liver targeted AAV vectors for gene therapy. In our previous studies, we have
successfully isolated several AAV mutants from the liver of chimeric mice with human hepatocyte xenografts in
the presence of human Nabs (IVIG) using the AAV shuffled capsid library approach. Specifically, BDRK001
(AAV mutant LP2-10) demonstrated a much higher ability to evade Nabs than any other AAV serotypes or
mutants. However, BDRK001 was not enhanced for transduction in human hepatocytes when compared to the
best natural serotype. In this application, we will use rational design strategy to generate novel AAV capsids by
variable region I (VRI) domain swapping of BDRK001 using natural serotypes or mutants with high human liver
tropism. This panel will then be evaluated in chimeric mice for human hepatocyte transduction (Aim 1) and
Nab evasion (Aim 2). Bedrock's long-term goal of this approach is low dose AAV gene therapy for the
successful treatment of a variety of liver diseases, independent of the patient's Nab prevalence.
腺相关病毒(AAV)载体已成功应用于各种疾病患者的临床试验,
紊乱两种基于AAV的基因治疗药物最近已被FDA批准。Luxturna一直是
价值85万美元的一次性治疗一种罕见形式的失明和Zolgensma售价210万美元
治疗脊髓性肌肉萎缩因此,基于AAV载体的基因治疗是一个越来越有吸引力的市场。
尽管在临床研究中取得了成功,但两个问题限制了AAV载体在患者中的更广泛应用
全身给药后需要肝靶向AAV基因治疗:低人肝细胞
转导和中和抗体(Nab)介导的AAV转导抑制。几种方法
已经探索了AAV转导增强或衣壳Nab逃避。AAV工程
衣壳是一种非常强大和流行的技术,已经广泛研究以开发新的
用于在动物模型中增强转导或体外Nab逃逸的AAV载体。然而已经
表明小鼠实验的结果并不能概括大型动物的结果,
灵长类动物和狗。因此,在动物细胞和器官中产生的AAV变体的数据可能无法翻译。
成功地应用于人类。最近,已经建立了具有人肝细胞的小鼠异种移植物模型。
用于开发用于基因治疗的人肝靶向AAV载体。在我们以前的研究中,我们有
成功地从具有人肝细胞异种移植物的嵌合小鼠的肝脏中分离了几种AAV突变体,
使用AAV改组衣壳文库方法检测人Nab(IVIG)的存在。具体而言,BDRK 001
(AAV突变体LP 2 -10)表现出比任何其它AAV血清型高得多的逃避Nab的能力,或
变种人然而,与BDRK 001相比,BDRK 001在人肝细胞中的转导没有增强。
最佳天然血清型。在本申请中,我们将使用合理的设计策略来产生新的AAV衣壳,
使用天然血清型或突变体进行的BDRK 001可变区I(VRI)结构域交换,
向性然后将在嵌合小鼠中评价该组的人肝细胞转导(Aim 1),
Nab回避(目标2)。基岩的长期目标,这种方法是低剂量的AAV基因治疗,
成功治疗各种肝病,与患者的Nab患病率无关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chengwen Li其他文献
Chengwen Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chengwen Li', 18)}}的其他基金
Novel strategy to block Nabs for AAV gene delivery
阻断 Nabs 进行 AAV 基因传递的新策略
- 批准号:
10570881 - 财政年份:2022
- 资助金额:
$ 26.11万 - 项目类别:
Novel strategy to block Nabs for AAV gene delivery
阻断 Nabs 进行 AAV 基因传递的新策略
- 批准号:
10416627 - 财政年份:2022
- 资助金额:
$ 26.11万 - 项目类别:
Development of AAV vectors for CF therapy
用于 CF 治疗的 AAV 载体的开发
- 批准号:
10544549 - 财政年份:2020
- 资助金额:
$ 26.11万 - 项目类别:
Development of AAV vectors for CF therapy
用于 CF 治疗的 AAV 载体的开发
- 批准号:
10117463 - 财政年份:2020
- 资助金额:
$ 26.11万 - 项目类别:
Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion
开发用于肝脏靶向和中和抗体逃避的人源化 AAV 载体
- 批准号:
10079155 - 财政年份:2020
- 资助金额:
$ 26.11万 - 项目类别:
Development of AAV vectors for CF therapy
用于 CF 治疗的 AAV 载体的开发
- 批准号:
10319017 - 财政年份:2020
- 资助金额:
$ 26.11万 - 项目类别:
Novel strategy to block AAV neutralizing anitbody activity
阻止 AAV 中和抗体活性的新策略
- 批准号:
10080225 - 财政年份:2020
- 资助金额:
$ 26.11万 - 项目类别:
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors
优化 AAV 载体以通过抑制剂递送血友病 FVa
- 批准号:
10372097 - 财政年份:2019
- 资助金额:
$ 26.11万 - 项目类别:
Enhance AAV Liver Transduction with Capsid Immune Evasion
通过衣壳免疫逃避增强 AAV 肝脏转导
- 批准号:
9098885 - 财政年份:2016
- 资助金额:
$ 26.11万 - 项目类别:
Enhance AAV Liver Transduction with Capsid Immune Evasion
通过衣壳免疫逃避增强 AAV 肝脏转导
- 批准号:
9893176 - 财政年份:2016
- 资助金额:
$ 26.11万 - 项目类别:
相似海外基金
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
- 批准号:
10685312 - 财政年份:2021
- 资助金额:
$ 26.11万 - 项目类别:
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
- 批准号:
10490872 - 财政年份:2021
- 资助金额:
$ 26.11万 - 项目类别:
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
- 批准号:
10345963 - 财政年份:2021
- 资助金额:
$ 26.11万 - 项目类别:
Development of Highly Functionalized Serum Albumins as Boron Delivery Carries to Tumor for Neutron Capture Therapy
开发高功能化血清白蛋白作为硼输送至肿瘤以进行中子捕获治疗
- 批准号:
17H02202 - 财政年份:2017
- 资助金额:
$ 26.11万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Studies on Asymmetric Nitroaldol Reaction using mutant albumins
突变体白蛋白不对称硝醛醇反应的研究
- 批准号:
16K05706 - 财政年份:2016
- 资助金额:
$ 26.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
SPIN LABELING STUDIES OF NORMAL RECOMBINANT & MUTANT HUMAN SERUM ALBUMINS
正常重组的旋转标记研究
- 批准号:
6118869 - 财政年份:1999
- 资助金额:
$ 26.11万 - 项目类别:
COPPER BINDING OF COMMERCIAL, NORMAL RECOMBINANT, & MUTANT HUMAN SERUM ALBUMINS
商业、正常重组的铜结合,
- 批准号:
6118864 - 财政年份:1999
- 资助金额:
$ 26.11万 - 项目类别:
Structure and Metabolism of the Serum Albumins Characteristic of Bisalbuminemia in Fowl
家禽双清蛋白血症血清白蛋白的结构与代谢特征
- 批准号:
67B6472 - 财政年份:1967
- 资助金额:
$ 26.11万 - 项目类别:
Structure and Metabolism of the Serum Albumins Characteristic of Bisalbuminemia
双清蛋白血症血清白蛋白的结构和代谢特征
- 批准号:
65B3344 - 财政年份:1965
- 资助金额:
$ 26.11万 - 项目类别: